Reinsurance News Bermuda Legacy Market Roundtable 2025

In November, Reinsurance News hosted a legacy re/insurance market roundtable, in partnership with RiverStone International, in Hamilton, Bermuda, which saw nine experts and leaders from across the run-off world debate current market dynamics, challenges, and opportunities for the future.

Roundtable participants noted that even with reduced headline activity in 2025, the level of sophistication, planning, and strategic intent behind legacy transactions continues to deepen, pointing to a sector that is steadily consolidating its role within the broader insurance ecosystem.

It was highlighted that the market has matured as the perception of legacy has shifted in a positive way, with one participant describing the sector as being in an entirely different place from where it was a decade ago.

Panellists agreed that merger and acquisition activity among re/insurers is expected to be a big opportunity for the legacy space, as speakers underlined the importance of partnerships and relationships, the role of IRLA and AIRROC, and also the supportive and collaborative approach of Bermuda’s regulator.

During the insightful session, roundtable participants also discussed shifts in cedent motivations, the evolution of structures, landmark deals, repeatability, syndication, the shift in the investor base to private equity, and also talent in the legacy sector and the potential influence of advanced technologies, and more.

On the day, the roundtable were joined by the following participants from across the legacy sector:

  • Jamie Saunders, Chief Underwriting Officer, RiverStone International.
  • Dan Sanford, M&A Managing Director, Enstar.
  • Adam Horridge, Director, Teneo.
  • Steve Ryland, MD & Global Head of Retrospective Solutions, Acrisure Re.
  • Steve Wallace, MD, Capital Advisory, Aon Reinsurance Solutions.
  • Jane Newton, Chief Financial Officer, Xitus Insurance.
  • Nick Miles, Partner, Kennedys.
  • Damian Cooper, Insurance Partner, PwC.
  • Thuan Ho, Head of Actuarial M&A, Compre.
 
Reinsurance News Bermuda Legacy Market Roundtable 2025

Transaction Overview

On December 31, 2025, Goodlife Solutions, Inc., the intermediate holding company of Blue Cross Blue Shield of Nebraska, Inc. (“BCBSNE”), completed a $100 million Senior Term Loan offering. BCBSNE is the leading health insurance provider in Nebraska, and the proceeds from the Senior Term Loan will be down streamed to BCBSNE in the form of a surplus note. This additional surplus will further strengthen BCBSNE’s already solid financial position as it advances its growth strategy across government programs.

BCBSNE is a member of the Blue Cross Blue Shield Association, which is comprised of over 30 plans and collectively provides healthcare coverage to nearly one third of all Americans. Founded in 1939, BCBSNE is the leading health insurer for group markets in Nebraska. The company generates approximately $2.6 billion in annual revenue and serves more than 600,000 members.

The Senior Term Loan was privately placed by a syndicate led by Synovus Bank.

Acrisure Re Corporate Advisory and Solutions (“ARCAS”) served as exclusive financial advisor to BCBSNE for this transaction.

Client Testimonial

“Acrisure’s responsiveness and reputation helped make this deal possible. Their preliminary work, connections, and due diligence guided us through our search for top quality partners that met our needs at favorable terms. Tom and his team walked with us through the entire process and helped us find the right deal and the right fit for our needs. I highly recommend Acrisure for anyone looking for a trusted advisor in this space.”

Acrisure Re Corporate Advisory & Solutions

ARCAS served as the exclusive financial advisor to Blue Cross Blue Shield of
Nebraska, providing:

  • Identification of syndicate participants
  • Advisory support on loan structuring and negotiations
*The experiences of the featured client are not indicative of the experience of all clients, and you should not expect similar results. Past performance may not be indicative of future results.